Wiley, British Journal of Haematology, 3(65), p. 377-379, 1987
DOI: 10.1111/j.1365-2141.1987.tb06873.x
Wiley, British Journal of Haematology, 2(64), p. 385-395, 1986
DOI: 10.1111/j.1365-2141.1986.tb04132.x
Full text: Unavailable
Between 1980 and 1985, 175 patients with acute leukaemia in first or subsequent complete remission (CR) were treated by chemotherapy of chemoradiotherapy followed by transfusion of autologous bone marrow cells that had been collected days or months previously. In 85 cases, autologous marrow cells were treated ex vivo with cytotoxic drugs or monoclonal antibodies with the intention of removing residual leukaemic cells. The actuarial relapse-free rate was 52% at 2 years. Of 89 patients autografted for acute non-lyphocytic (myeloid) leukaemia (ANLL), 60 were treated in first remission and 18 in second CR; their relapse-free rates at 2 years were 67% and 41% respectively (P